Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 10/2019

01-10-2019 | Pleural Mesothelioma | Concise Research Reports

Communicating a Prognosis: a Randomized Trial of Survival Rate Language

Authors: Eric P. Silver, MS, Stephen B. Broomell, PhD, Alexander L. Davis, PhD, Douglas B. White, MD, Tamar Krishnamurti, PhD

Published in: Journal of General Internal Medicine | Issue 10/2019

Login to get access

Excerpt

As medical practice transitions toward shared decision-making between physicians and patients, it is essential that prognostic information is clearly communicated.1 Laypeople are able to make reasonable statistical inferences about familiar domains.2 However, Kaplan-Meier curves, commonly used by physicians in estimating survival rates over time, are unfamiliar to patients. We test two prognoses, which communicate cumulative mortality and duration, and find lay understandings are more affected by the chosen time period than survival probability when estimating survival duration. …
Literature
1.
Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst. 2011;103(19):1436–1443.CrossRef
2.
Griffiths TL, Tenenbaum JB. Optimal predictions in everyday cognition. Psychol Sci. 2006;17(9):767–773.CrossRef
3.
Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, ... Baldini EH. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117(1):54–65.CrossRef
Metadata
Title
Communicating a Prognosis: a Randomized Trial of Survival Rate Language
Authors
Eric P. Silver, MS
Stephen B. Broomell, PhD
Alexander L. Davis, PhD
Douglas B. White, MD
Tamar Krishnamurti, PhD
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 10/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05056-w

Other articles of this Issue 10/2019

Journal of General Internal Medicine 10/2019 Go to the issue

OriginalPaper

Comparing Shared Patient Networks Across Payers

Letter

Physicians Interrupting Patients

Letter to the Editor

Letter to the Editor

Clinical Practice: Clinical Images

Skin Bends: a Cutaneous Manifestation of Decompression Sickness

Concise Research Reports

Change in Faculty Perceptions of Burnout and Work Life in an Academic General Medicine Clinic: a Pre-Post Study

Capsule Commentary

Capsule Commentary on Baumgartner et al., Aspirin Compared with Anticoagulation to Prevent Venous Thromboembolism after Knee or Hip Arthroplasty: a Large Retrospective Cohort Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits